Editorial: Angiotensin inhibition.
D000409:Alanine / Q000494:pharmacology; D000450:Aldosterone / Q000378:metabolism; D000804:Angiotensin II / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000494:pharmacology / Q000502:physiology; D000806:Angiotensin-Converting Enzyme Inhibitors; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000201:enzymology / Q000503:physiopathology; D006977:Hypertension, Renal / Q000503:physiopathology; D009842:Oligopeptides / Q000494:pharmacology / Q000627:therapeutic use; D012083:Renin / Q000097:blood / Q000378:metabolism / Q000502:physiology; D012521:Sarcosine / Q000494:pharmacology
D000806:Angiotensin-Converting Enzyme Inhibitors; D009842:Oligopeptides; D000804:Angiotensin II; D000450:Aldosterone; D012083:Renin; D000409:Alanine; D012521:Sarcosine